Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $340.0 million.

  • Ultragenyx Pharmaceutical's Total Current Liabilities rose 1930.26% to $340.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.0 million, marking a year-over-year increase of 1930.26%. This contributed to the annual value of $344.2 million for FY2024, which is 2272.03% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Total Current Liabilities is $340.0 million, which was up 1930.26% from $293.2 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Total Current Liabilities peaked at $344.2 million during Q4 2024, and registered a low of $127.0 million during Q1 2021.
  • Its 5-year average for Total Current Liabilities is $237.8 million, with a median of $245.6 million in 2024.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Total Current Liabilities tumbled by 4217.1% in 2021, and later soared by 7363.75% in 2022.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Total Current Liabilities stood at $181.4 million in 2021, then soared by 44.02% to $261.2 million in 2022, then rose by 7.36% to $280.4 million in 2023, then grew by 22.72% to $344.2 million in 2024, then dropped by 1.2% to $340.0 million in 2025.
  • Its Total Current Liabilities was $340.0 million in Q3 2025, compared to $293.2 million in Q2 2025 and $291.7 million in Q1 2025.